Livagen

Quickstart Highlights

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator studied for its effects on peptidase inhibition and epigenetic modulation in aging tissues. Preclinical research demonstrates Livagen strongly inhibits enkephalin-degrading enzymes and induces heterochromatin decondensation with gene reactivation in aged cells. No standardized human dosing exists; this educational protocol presents a once-daily subcutaneous 20-day course (repeated two to three times per year) based on analogy with similar peptide bioregulators.

• Reconstitute: Add 2.0 mL bacteriostatic water (BAC) per labelled 20 mg vial. Calculations assume a final volume of 2.0 mL and nominal 10 mg/mL.
• Typical daily range: 1.0–2.0 mg once daily for a 20-day course (1.0 mg for Days 1–5, then 2.0 mg); repeat 2–3 times per year.
• Scale conversion: At 10 mg/mL, 1 U-100 unit = 0.01 mL = 0.1 mg (100 mcg). Verify the actual device markings and calibration.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the 20-day course regimen.

• Goal: Support cellular homeostasis and regenerative processes in aging tissues.
• Schedule: One daily subcutaneous injection for a 20-day course (10 days minimum); repeat two to three times per year with at least 3 months between courses.
• Dose Range: 1.0–2.0 mg daily; 1.0 mg for Days 1–5, then 2.0 mg.
• Reconstitution: 2.0 mL BAC per labelled 20 mg vial; nominal 10 mg/mL under the stated final-volume assumption.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested 20-day course (Khavinson-style bioregulator schedule).

• Start: 1.0 mg daily for Days 1–5 to assess tolerance.
• Target: 2.0 mg daily from Day 6 through Day 20.
• Frequency: Once per day (subcutaneous).
• Course Length: 20 days standard (10 days minimum); 2–3 courses per year with at least 3 months between courses. Do not extend continuously.
• Timing: Any consistent time; rotate injection sites daily.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• No standardized human clinical administration studies exist for Livagen; dosing is extrapolated from preclinical data and similar peptide bioregulators.

How This Works

Livagen’s mechanisms involve peptidase inhibition and epigenetic modulation. The peptide strongly inhibits enkephalin-degrading enzymes (IC50 ≈ 20 μM) in human serum, which may prolong endogenous enkephalin activity. Notably, this occurs without direct opioid receptor binding. In aging cells, Livagen has been shown to induce heterochromatin decondensation and reactivate ribosomal genes. Preclinical studies in rat liver organ cultures demonstrated enhanced cellular structure and regenerative processes, while oral administration in aged rats shifted digestive enzyme activities toward youthful patterns.

Potential Benefits & Side Effects

Observations from preclinical and in vitro literature.

• Supports inhibition of enkephalin-degrading enzymes, potentially prolonging endogenous enkephalin signaling.
• May modulate gene expression and chromatin structure in aging tissues.
• Preclinical evidence suggests support for cellular homeostasis and regenerative capacity.
• In aged rodents, oral dosing normalized digestive enzyme activity toward youthful levels.
• No human clinical administration studies have been reported; side effect profile in humans is unknown.
• Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced, nutrient-dense diet to support cellular health.
• Engage in regular physical activity to reinforce metabolic and regenerative adaptations.
• Prioritize sleep quality and stress management to support overall homeostasis.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
• Dispose of used syringes immediately in a sharps container.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Amino Labs